Covalon Technologies Ltd. (COV.V)
CAD 3.44
(2.99%)
CAD 3.44
(2.99%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -7.23 Million CAD | 39.19% |
| 2022 | -11.89 Million CAD | 41.58% |
| 2021 | -20.35 Million CAD | -217.02% |
| 2020 | 17.39 Million CAD | 104.13% |
| 2019 | 8.52 Million CAD | 315.41% |
| 2018 | -3.95 Million CAD | 4.81% |
| 2017 | -4.15 Million CAD | -185.75% |
| 2016 | -1.45 Million CAD | -217.49% |
| 2015 | -458.08 Thousand CAD | 84.28% |
| 2014 | -2.91 Million CAD | -2389.04% |
| 2013 | -117.08 Thousand CAD | 89.75% |
| 2012 | -1.14 Million CAD | 76.01% |
| 2011 | -4.76 Million CAD | 18.42% |
| 2010 | -5.83 Million CAD | 3.28% |
| 2009 | -6.03 Million CAD | -70.84% |
| 2008 | -3.53 Million CAD | 48.92% |
| 2007 | -6.91 Million CAD | -38.04% |
| 2006 | -5.01 Million CAD | -678.2% |
| 2005 | -644 Thousand CAD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q3 | -8.32 Million CAD | -38.68% |
| 2024 Q2 | -6 Million CAD | 13.17% |
| 2024 Q1 | -6.91 Million CAD | 4.38% |
| 2023 Q1 | -12.06 Million CAD | -1.44% |
| 2023 Q2 | -8.89 Million CAD | 26.24% |
| 2023 Q3 | -7.5 Million CAD | 15.62% |
| 2023 FY | -7.23 Million CAD | 39.19% |
| 2023 Q4 | -7.23 Million CAD | 3.68% |
| 2022 FY | -11.89 Million CAD | 41.58% |
| 2022 Q2 | -17.25 Million CAD | 13.38% |
| 2022 Q3 | -11.78 Million CAD | 31.69% |
| 2022 Q1 | -19.91 Million CAD | 2.15% |
| 2022 Q4 | -11.89 Million CAD | -0.91% |
| 2021 Q4 | -20.35 Million CAD | -225.13% |
| 2021 Q1 | 17.4 Million CAD | 0.06% |
| 2021 Q2 | 16.58 Million CAD | -4.71% |
| 2021 Q3 | 16.26 Million CAD | -1.92% |
| 2021 FY | -20.35 Million CAD | -217.02% |
| 2020 Q3 | 17.33 Million CAD | -3.69% |
| 2020 Q2 | 18 Million CAD | 5.91% |
| 2020 FY | 17.39 Million CAD | 104.13% |
| 2020 Q1 | 16.99 Million CAD | 99.47% |
| 2020 Q4 | 17.39 Million CAD | 0.33% |
| 2019 Q3 | 16.66 Million CAD | 1.72% |
| 2019 FY | 8.52 Million CAD | 315.41% |
| 2019 Q2 | 16.38 Million CAD | 12.66% |
| 2019 Q1 | 14.53 Million CAD | 467.52% |
| 2019 Q4 | 8.52 Million CAD | -48.86% |
| 2018 Q3 | -1.72 Million CAD | 6.13% |
| 2018 Q1 | -4.21 Million CAD | -1.48% |
| 2018 FY | -3.95 Million CAD | 4.81% |
| 2018 Q4 | -3.95 Million CAD | -129.82% |
| 2018 Q2 | -1.83 Million CAD | 56.52% |
| 2017 Q1 | -1.22 Million CAD | 15.99% |
| 2017 FY | -4.15 Million CAD | -185.75% |
| 2017 Q4 | -4.15 Million CAD | -62.89% |
| 2017 Q3 | -2.55 Million CAD | -416.34% |
| 2017 Q2 | -494.11 Thousand CAD | 59.56% |
| 2016 Q3 | -670.95 Thousand CAD | -352.04% |
| 2016 Q2 | 266.21 Thousand CAD | 765.55% |
| 2016 Q4 | -1.45 Million CAD | -116.76% |
| 2016 FY | -1.45 Million CAD | -217.49% |
| 2016 Q1 | -39.99 Thousand CAD | 91.27% |
| 2015 Q1 | -2.9 Million CAD | 0.28% |
| 2015 Q4 | -458.08 Thousand CAD | 81.7% |
| 2015 FY | -458.08 Thousand CAD | 84.28% |
| 2015 Q2 | -2.36 Million CAD | 18.76% |
| 2015 Q3 | -2.5 Million CAD | -6.03% |
| 2014 FY | -2.91 Million CAD | -2389.04% |
| 2014 Q1 | -4.16 Million CAD | -3460.4% |
| 2014 Q3 | -3.53 Million CAD | 2.32% |
| 2014 Q4 | -2.91 Million CAD | 17.52% |
| 2014 Q2 | -3.61 Million CAD | 13.23% |
| 2013 Q1 | -727.02 Thousand CAD | 36.37% |
| 2013 Q4 | -117.08 Thousand CAD | 73.35% |
| 2013 FY | -117.08 Thousand CAD | 89.75% |
| 2013 Q3 | -439.36 Thousand CAD | -5.61% |
| 2013 Q2 | -416.03 Thousand CAD | 42.78% |
| 2012 Q3 | -1.59 Million CAD | 44.1% |
| 2012 Q2 | -2.85 Million CAD | 27.37% |
| 2012 Q1 | -3.92 Million CAD | 17.57% |
| 2012 FY | -1.14 Million CAD | 76.01% |
| 2012 Q4 | -1.14 Million CAD | 28.32% |
| 2011 FY | -4.76 Million CAD | 18.42% |
| 2011 Q4 | -4.76 Million CAD | -79.07% |
| 2011 Q3 | -2.65 Million CAD | 22.48% |
| 2011 Q2 | -3.43 Million CAD | 30.83% |
| 2011 Q1 | -4.96 Million CAD | 15.03% |
| 2010 Q3 | -6.43 Million CAD | -29.4% |
| 2010 Q4 | -5.83 Million CAD | 9.23% |
| 2010 FY | -5.83 Million CAD | 3.28% |
| 2010 Q1 | -5.42 Million CAD | 10.07% |
| 2010 Q2 | -4.97 Million CAD | 8.44% |
| 2009 Q4 | -6.03 Million CAD | 22.49% |
| 2009 Q3 | -7.78 Million CAD | 13.83% |
| 2009 Q2 | -9.03 Million CAD | 16.44% |
| 2009 Q1 | -10.81 Million CAD | -206.14% |
| 2009 FY | -6.03 Million CAD | -70.84% |
| 2008 Q2 | -5.41 Million CAD | 14.03% |
| 2008 Q4 | -3.53 Million CAD | 74.55% |
| 2008 Q3 | -13.88 Million CAD | -156.55% |
| 2008 FY | -3.53 Million CAD | 48.92% |
| 2008 Q1 | -6.29 Million CAD | 8.98% |
| 2007 Q3 | -6.98 Million CAD | -8.16% |
| 2007 FY | -6.91 Million CAD | -38.04% |
| 2007 Q1 | -4.56 Million CAD | 8.92% |
| 2007 Q4 | -6.91 Million CAD | 0.96% |
| 2007 Q2 | -6.45 Million CAD | -41.48% |
| 2006 Q3 | -5.45 Million CAD | 8.62% |
| 2006 Q2 | -5.97 Million CAD | -4190.85% |
| 2006 Q1 | -139.23 Thousand CAD | 78.38% |
| 2006 Q4 | -5.01 Million CAD | 8.21% |
| 2006 FY | -5.01 Million CAD | -678.2% |
| 2005 FY | -644 Thousand CAD | 0.0% |
| 2005 Q1 | -1.78 Million CAD | 0.0% |
| 2005 Q2 | -1.8 Million CAD | -1.09% |
| 2005 Q4 | -644 Thousand CAD | 45.65% |
| 2005 Q3 | -1.18 Million CAD | 34.31% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Arch Biopartners Inc. | 4.18 Million CAD | 272.816% |
| Hemostemix Inc. | 4.16 Million CAD | 273.597% |
| Universal Ibogaine Inc. | 1.01 Million CAD | 814.907% |
| Kane Biotech Inc. | 7.52 Million CAD | 196.087% |
| MedMira Inc. | 9.25 Million CAD | 178.118% |
| Marvel Biosciences Corp. | 443.37 Thousand CAD | 1731.156% |
| NervGen Pharma Corp. | -11.46 Million CAD | 36.905% |
| XORTX Therapeutics Inc. | -4.53 Million CAD | -59.619% |